FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1966765744> ?p ?o ?g. }

• W1966765744 endingPage "534.e2" @default.
• W1966765744 startingPage "527" @default.
• W1966765744 abstract "Background & AimsThe spontaneous seroclearance of hepatitis B e antigen (HBeAg) and hepatitis B virus (HBV) DNA are important markers of progression of chronic HBV infection. We performed a long-term cohort study to elucidate the incidence and determinants of HBeAg and HBV DNA seroclearance in patients with chronic hepatitis B.MethodsA total of 1289 participants with a serum HBV DNA level of 10,000 copies/mL or more and without cirrhosis when the study began (1991–1992) were followed up until June 2004. A subset of patients that tested positive for HBeAg at baseline (n = 439) was included in the analysis of HBeAg seroclearance. Cox proportional hazards models were used to estimate seroclearance rate ratios for various determinants associated with the outcomes.ResultsAfter 3161.2 person-years of follow-up evaluation, HBeAg seroclearance occurred in 187 participants (incidence rate, 5.9 per 100 person-years). The cumulative lifetime incidence of HBeAg seroclearance among patients who were 30 to 40, or 50, 60, 70, or 74 years old was 38.8%, 69.4%, 81.9%, 89.1%, and 95.5%, respectively. Major predictors of HBeAg seroclearance included female sex, genotype B, the precore 1896 mutant, increased serum levels of alanine aminotransferase, and low baseline serum levels of HBV DNA. The median (interquartile range) serum level of HBV DNA at the time of HBeAg seroclearance was 177,801 copies/mL (4941–3,247,560 copies/mL). HBV DNA seroclearance occurred in 199 participants (15.4%) during the mean follow-up period of 7.8 years (incidence rate, 1.97 per 100 person-years). The cumulative lifetime incidence of HBV DNA seroclearance at 40, 50, 60, 70, and 77 years old was 10.0%, 25.0%, 38.8%, 54.2%, and 82.8%, respectively. Lower levels of HBV DNA at study entry and among those with the precore 1896 wild-type variant were associated with an increased rate of HBV DNA seroclearance. Among individuals who were HBeAg-seropositive at study entry and cleared serum HBV DNA during the follow-up period, 89% had cleared HBeAg by the time they had an undetectable serum level of HBV DNA.ConclusionsSerum level of HBV DNA is the most important predictor of seroclearance of HBeAg and HBV DNA. This finding supports current clinical guidelines for antiviral treatments of chronic hepatitis B. The spontaneous seroclearance of hepatitis B e antigen (HBeAg) and hepatitis B virus (HBV) DNA are important markers of progression of chronic HBV infection. We performed a long-term cohort study to elucidate the incidence and determinants of HBeAg and HBV DNA seroclearance in patients with chronic hepatitis B. A total of 1289 participants with a serum HBV DNA level of 10,000 copies/mL or more and without cirrhosis when the study began (1991–1992) were followed up until June 2004. A subset of patients that tested positive for HBeAg at baseline (n = 439) was included in the analysis of HBeAg seroclearance. Cox proportional hazards models were used to estimate seroclearance rate ratios for various determinants associated with the outcomes. After 3161.2 person-years of follow-up evaluation, HBeAg seroclearance occurred in 187 participants (incidence rate, 5.9 per 100 person-years). The cumulative lifetime incidence of HBeAg seroclearance among patients who were 30 to 40, or 50, 60, 70, or 74 years old was 38.8%, 69.4%, 81.9%, 89.1%, and 95.5%, respectively. Major predictors of HBeAg seroclearance included female sex, genotype B, the precore 1896 mutant, increased serum levels of alanine aminotransferase, and low baseline serum levels of HBV DNA. The median (interquartile range) serum level of HBV DNA at the time of HBeAg seroclearance was 177,801 copies/mL (4941–3,247,560 copies/mL). HBV DNA seroclearance occurred in 199 participants (15.4%) during the mean follow-up period of 7.8 years (incidence rate, 1.97 per 100 person-years). The cumulative lifetime incidence of HBV DNA seroclearance at 40, 50, 60, 70, and 77 years old was 10.0%, 25.0%, 38.8%, 54.2%, and 82.8%, respectively. Lower levels of HBV DNA at study entry and among those with the precore 1896 wild-type variant were associated with an increased rate of HBV DNA seroclearance. Among individuals who were HBeAg-seropositive at study entry and cleared serum HBV DNA during the follow-up period, 89% had cleared HBeAg by the time they had an undetectable serum level of HBV DNA. Serum level of HBV DNA is the most important predictor of seroclearance of HBeAg and HBV DNA. This finding supports current clinical guidelines for antiviral treatments of chronic hepatitis B." @default.
• W1966765744 created "2016-06-24" @default.
• W1966765744 creator A5001718162 @default.
• W1966765744 creator A5003548291 @default.
• W1966765744 creator A5008054592 @default.
• W1966765744 creator A5021618021 @default.
• W1966765744 creator A5023905903 @default.
• W1966765744 creator A5036779615 @default.
• W1966765744 creator A5059993079 @default.
• W1966765744 creator A5071130347 @default.
• W1966765744 creator A5071184898 @default.
• W1966765744 creator A5075400058 @default.
• W1966765744 creator A5080447795 @default.
• W1966765744 date "2012-05-01" @default.
• W1966765744 modified "2023-10-18" @default.
• W1966765744 title "Incidence and Determinants of Spontaneous Seroclearance of Hepatitis B e Antigen and DNA in Patients With Chronic Hepatitis B" @default.
• W1966765744 cites W1887371688 @default.
• W1966765744 cites W1906881483 @default.
• W1966765744 cites W1978464644 @default.
• W1966765744 cites W1979722884 @default.
• W1966765744 cites W1996594959 @default.
• W1966765744 cites W2004100607 @default.
• W1966765744 cites W2017537010 @default.
• W1966765744 cites W2031317669 @default.
• W1966765744 cites W2044565887 @default.
• W1966765744 cites W2069711807 @default.
• W1966765744 cites W2070589063 @default.
• W1966765744 cites W2078751603 @default.
• W1966765744 cites W2080503023 @default.
• W1966765744 cites W2086055165 @default.
• W1966765744 cites W2087564721 @default.
• W1966765744 cites W2092961332 @default.
• W1966765744 cites W2094281766 @default.
• W1966765744 cites W2104389844 @default.
• W1966765744 cites W2115123213 @default.
• W1966765744 cites W2120128540 @default.
• W1966765744 cites W2134844770 @default.
• W1966765744 cites W2142184944 @default.
• W1966765744 cites W2162645287 @default.
• W1966765744 cites W2167744756 @default.
• W1966765744 cites W2314866596 @default.
• W1966765744 cites W2943463865 @default.
• W1966765744 cites W3030265267 @default.
• W1966765744 cites W4256193732 @default.
• W1966765744 doi "https://doi.org/10.1016/j.cgh.2011.12.019" @default.
• W1966765744 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22178461" @default.
• W1966765744 hasPublicationYear "2012" @default.
• W1966765744 type Work @default.
• W1966765744 sameAs 1966765744 @default.
• W1966765744 citedByCount "30" @default.
• W1966765744 countsByYear W19667657442013 @default.
• W1966765744 countsByYear W19667657442014 @default.
• W1966765744 countsByYear W19667657442015 @default.
• W1966765744 countsByYear W19667657442016 @default.
• W1966765744 countsByYear W19667657442017 @default.
• W1966765744 countsByYear W19667657442018 @default.
• W1966765744 countsByYear W19667657442019 @default.
• W1966765744 countsByYear W19667657442021 @default.
• W1966765744 countsByYear W19667657442022 @default.
• W1966765744 countsByYear W19667657442023 @default.
• W1966765744 crossrefType "journal-article" @default.
• W1966765744 hasAuthorship W1966765744A5001718162 @default.
• W1966765744 hasAuthorship W1966765744A5003548291 @default.
• W1966765744 hasAuthorship W1966765744A5008054592 @default.
• W1966765744 hasAuthorship W1966765744A5021618021 @default.
• W1966765744 hasAuthorship W1966765744A5023905903 @default.
• W1966765744 hasAuthorship W1966765744A5036779615 @default.
• W1966765744 hasAuthorship W1966765744A5059993079 @default.
• W1966765744 hasAuthorship W1966765744A5071130347 @default.
• W1966765744 hasAuthorship W1966765744A5071184898 @default.
• W1966765744 hasAuthorship W1966765744A5075400058 @default.
• W1966765744 hasAuthorship W1966765744A5080447795 @default.
• W1966765744 hasConcept C119060515 @default.
• W1966765744 hasConcept C120665830 @default.
• W1966765744 hasConcept C121332964 @default.
• W1966765744 hasConcept C126322002 @default.
• W1966765744 hasConcept C203014093 @default.
• W1966765744 hasConcept C207103383 @default.
• W1966765744 hasConcept C2522874641 @default.
• W1966765744 hasConcept C2775940106 @default.
• W1966765744 hasConcept C2777214474 @default.
• W1966765744 hasConcept C2777382497 @default.
• W1966765744 hasConcept C2777410769 @default.
• W1966765744 hasConcept C2780593183 @default.
• W1966765744 hasConcept C44249647 @default.
• W1966765744 hasConcept C61511704 @default.
• W1966765744 hasConcept C71924100 @default.
• W1966765744 hasConcept C72563966 @default.
• W1966765744 hasConcept C88879693 @default.
• W1966765744 hasConcept C90924648 @default.
• W1966765744 hasConceptScore W1966765744C119060515 @default.
• W1966765744 hasConceptScore W1966765744C120665830 @default.
• W1966765744 hasConceptScore W1966765744C121332964 @default.
• W1966765744 hasConceptScore W1966765744C126322002 @default.
• W1966765744 hasConceptScore W1966765744C203014093 @default.
• W1966765744 hasConceptScore W1966765744C207103383 @default.
• W1966765744 hasConceptScore W1966765744C2522874641 @default.
• W1966765744 hasConceptScore W1966765744C2775940106 @default.

• next